NLRP3 and rheumatoid arthritis: Furthermore, we developed a TIPTP (p22 inhibitor) that showed considerably improved potency and selectivity than the previously reported N8 peptide-mimetic small molecule [23 Particularly, we show that NLRP3 inflammasomes induced by ROS, in vivo, can be inhibited by targeting the p22hox–Rubicon interaction by p22 inhibitor, which also showed enhance therapeutic effects ex vivo on monocytes from healthy individuals and synovial fluid cells from RA patients, and in mouse models for RA.